<DOC>
	<DOCNO>NCT00241475</DOCNO>
	<brief_summary>To evaluate activity gefitinib subject relapse prostate cancer estimate PSA response rate study closure</brief_summary>
	<brief_title>Gefitinib Treatment First Relapse Prostate Cancer Beyond Prostatectomy Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Relapsed prostate cancer prostatectomy radiotherapy PSA level 10 ng/mL Lymph node negative Metastasis negative Withdrawal hormone therapy least 6 month entry study Written inform consent Metastatic disease Hormonal treatment 6 month study entry Concomitant radiotherapy , surgery and/or chemotherapy ILD</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Cancer Prostate</keyword>
</DOC>